To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

Antibiotics Causing Adverse Effects in Therapeutic Use Clinical Trial

Official title:
A Phase 1, Randomized, Double-Blind Study to Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ) After Intravenous Administrations in Healthy Volunteers

Status Completed

Clinical Trial Summary

To evaluate the safety, tolerability and pharmacokinetics (PK) of multiple IV doses of FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) administered every 8 hours (q8h) in healthy adult volunteers for 10 days.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Antibiotics Causing Adverse Effects in Therapeutic Use

Clinical Trial Details

NCT number	NCT03622008
Study type	Interventional
Source	Wockhardt
Contact
Status	Completed
Phase	Phase 1
Start date	March 23, 2018
Completion date	May 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04230746` - Effect of Antibiotics on Urinary Microbiome	Early Phase 1
Recruiting	`NCT04705259` - A Multimodal Intervention to Optimise Antimicrobial Use in Residential Aged Care Facilities (ENGAGEMENT Study)	N/A
Not yet recruiting	`NCT04980170` - Clindamycin Versus Amoxicillin With Clavulanic Acid in Prevention of Early Dental Implants Failure	Early Phase 1
Enrolling by invitation	`NCT05020418` - De-Implementation of Inappropriate Antimicrobial Use After Cardiac Device Procedures	N/A
Recruiting	`NCT05040334` - Role of Prophylactic Antibiotics in Preventing Pelvic Infection After Surgical Evacuation	Phase 4
Enrolling by invitation	`NCT05224687` - Utility Assessment of a Pharmacy-to-Dose Daptomycin